Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.

Chen X, Xu S, McClelland M, Rahmatpanah F, Sawyers A, Jia Z, Mercola D.

PLoS One. 2012;7(9):e45178. doi: 10.1371/journal.pone.0045178. Epub 2012 Sep 28.

2.

A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.

Agell L, Hernández S, Nonell L, Lorenzo M, Puigdecanet E, de Muga S, Juanpere N, Bermudo R, Fernández PL, Lorente JA, Serrano S, Lloreta J.

Am J Pathol. 2012 Nov;181(5):1585-94. doi: 10.1016/j.ajpath.2012.08.005. Erratum in: Am J Pathol. 2013 Feb;182(2):610.

PMID:
23083832
3.

Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression.

Zhao H, Logothetis CJ, Gorlov IP.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):252-9. doi: 10.1038/pcan.2010.9. Epub 2010 Apr 13.

4.

Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.

Goh LK, Liem N, Vijayaraghavan A, Chen G, Lim PL, Tay KJ, Chang M, Low JS, Joshi A, Huang HH, Kalaw E, Tan PH, Hsieh WS, Yong WP, Alumkal J, Sim HG.

PLoS One. 2014 Mar 13;9(3):e91666. doi: 10.1371/journal.pone.0091666. eCollection 2014.

5.

Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.

Pascal LE, Vêncio RZ, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY.

BMC Cancer. 2009 Dec 18;9:452. doi: 10.1186/1471-2407-9-452.

6.

Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.

Li CR, Su JJ, Wang WY, Lee MT, Wang TY, Jiang KY, Li CF, Hsu JM, Chen CK, Chen M, Jiang SS, Weaver VM, Tsai KK.

Am J Pathol. 2013 Feb;182(2):363-74. doi: 10.1016/j.ajpath.2012.10.024. Epub 2012 Dec 4.

7.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

8.

Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.

Mathieu R, Evrard B, Fromont G, Rioux-Leclercq N, Godet J, Cathelineau X, Guillé F, Primig M, Chalmel F.

Prostate. 2013 Jul;73(10):1103-14. doi: 10.1002/pros.22659. Epub 2013 Mar 26.

PMID:
23532770
9.

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.

Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U.

Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71. doi: 10.1007/s10555-013-9470-4. Review.

10.

A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J.

Eur Urol. 2013 Dec;64(6):941-50. doi: 10.1016/j.eururo.2013.02.039. Epub 2013 Mar 7.

PMID:
23490727
11.

A robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinoma.

Toh SH, Prathipati P, Motakis E, Kwoh CK, Yenamandra SP, Kuznetsov VA.

BMC Genomics. 2011 Nov 30;12 Suppl 3:S24. doi: 10.1186/1471-2164-12-S3-S24. Epub 2011 Nov 30.

12.

Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I.

PLoS One. 2011;6(5):e18640. doi: 10.1371/journal.pone.0018640. Epub 2011 May 18.

13.

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.

PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.

14.

Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.

Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A.

J Pathol. 2005 Feb;205(3):359-76.

PMID:
15532095
15.

GREB1 tissue expression is associated with organ-confined prostate cancer.

Antunes AA, Leite KR, Reis ST, Sousa-Canavez JM, Camara-Lopes LH, Dall'oglio MF, Srougi M.

Urol Oncol. 2012 Jan-Feb;30(1):16-20. doi: 10.1016/j.urolonc.2009.09.014. Epub 2009 Nov 27.

PMID:
19945309
16.

Expression changes in the stroma of prostate cancer predict subsequent relapse.

Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, Sawyers A, Sutton M, McClelland M, Mercola D.

PLoS One. 2012;7(8):e41371. doi: 10.1371/journal.pone.0041371. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/7de63575-e5c9-4f1d-bb45-fc6420e92c71.

17.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.

Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S.

Prostate. 2009 Sep 15;69(13):1398-403. doi: 10.1002/pros.20988.

PMID:
19479898
18.

Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles.

Bălăcescu L, Bălăcescu O, Crişan N, Fetica B, Petruţ B, Bungărdean C, Rus M, Tudoran O, Meurice G, Irimie A, Dragoş N, Berindan-Neagoe I.

Rom J Morphol Embryol. 2011;52(4):1195-202.

19.

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM.

JAMA. 2002 Apr 3;287(13):1662-70.

PMID:
11926890
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk